A new clinical trial explored whether raising cellular NAD⁺ levels with high-dose nicotinamide riboside could influence lingering neurological and physical symptoms in long-COVID. Millions of people around the world continue to live with persistent symptoms after a COVID-19 infection, a condition known as long COVID. These ongoing problems can affect people of all ages and […]
Source link